Portfolio company
Bamboo Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops gene therapies for patients with rare neuromuscular and central nervous system diseases, including Duchenne muscular dystrophy.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Exonics
This company develops gene editing therapies for patients with Duchenne muscular dystrophy and other severe genetic neuromuscular diseases.
Exonics Therapeutics
The company develops gene editing therapies for patients with Duchenne muscular dystrophy and other genetic neuromuscular diseases.
Myosana Therapeutics, Inc.
This company develops non-viral gene therapies for patients with cardiac and neuromuscular diseases, including Duchenne muscular dystrophy and X-linked myotubular myopathy.
MyoGene Bio
This company develops gene-editing therapies to treat Duchenne muscular dystrophy and other muscle-wasting diseases for patients worldwide.
MyoGene Bio
This company develops gene-editing therapies to treat patients with Duchenne muscular dystrophy by restoring production of the dystrophin protein.
Capricor
This biotechnology company develops cell and exosome-based therapies to treat Duchenne muscular dystrophy and other serious diseases for patients.
Uncommon Therapeutics
This company develops gene-based medicines for patients with rare neurodevelopmental disorders, with an initial focus on treating Rett Syndrome.
Neurogene Inc
This company develops genetic medicines and gene therapies to treat patients and families affected by rare neurological diseases including Rett syndrome and Batten disease.